Novo Nordisk stock price today stands at $130.95, reflecting a 1.1% gain driven by robust Q1 forecasts. Market watchers see accelerated growth in the pharma sector boosting valuation multiples above the 30x earnings mark. Morgan Stanley downgraded Novo Nordisk A/S (NYSE:NVO) from Equal-Weight to Underweight on September 29, 2025, and dropped its price target from $53.20 to $42. The analyst cited a “tough path ahead” due to pricing pressures, escalating competition, and slowing U.S. prescription patterns. In premarket trade, shares dropped more than 3%. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Novo Nordisk stock price stayed firm at $131.20, driven by solid dividend payout announcements. The stock’s yield attractively complements its growth trajectory, appealing to both income and growth investors.
